Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma

被引:6
|
作者
Nakanishi, Keita [1 ]
Sakakura, Noriaki [1 ]
Matsui, Takuya [1 ]
Ueno, Harushi [1 ]
Nakada, Takeo [1 ]
Oya, Yuko [2 ]
Shimizu, Junichi [2 ]
Hida, Toyoaki [2 ]
Hosoda, Waki [3 ]
Kuroda, Hiroaki [1 ]
机构
[1] Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi, Japan
[2] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
[3] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan
关键词
Lung cancer; pulmonary pleomorphic carcinoma; surgery; PD-L1; CELL-CARCINOMA; SPINDLE-CELL; LUNG; CHEMOTHERAPY; MUTATION;
D O I
10.21873/anticanres.13782
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Pulmonary pleomorphic carcinoma (PPC) is rare, and few studies have reported its features. We assessed the clinicopathological features, surgical outcomes, oncogenic status and programmed death-ligand 1 (PD-L1) expression of PPC. Patients and Methods: We retrospectively reviewed data from 22 consecutive patients who underwent resection of PPC between 2007 and 2017. Results: The predominant tissue type of the epithelial component was adenocarcinoma in 15 patients (68%) and the others in 7 patients (32%), and the 3-year disease-free survival rate tended to be better in patients with an adenocarcinoma component compared to patients with another component (40.0% vs. 17.1%, p=0.059). PD-L1 expression was observed in all eight tumors whose PD-L1 status could be examined and high PD-L1 expression (>= 50%) was frequent (5/8, 63%). Conclusion: A predominant adenocarcinoma epithelial component in PPC might be associated with better survival outcomes and high PD-L1 expression might be frequent in PPC.
引用
收藏
页码:5789 / 5795
页数:7
相关论文
共 50 条
  • [1] PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma
    Hisakane, Kakeru
    Seike, Masahiro
    Sugano, Teppei
    Matsuda, Kuniko
    Kunugi, Shinobu
    Nakamichi, Shinji
    Matsumoto, Masaru
    Miyanaga, Akihiko
    Noro, Rintaro
    Minegishi, Yuji
    Kubota, Kaoru
    Gemma, Akihiko
    ANTICANCER RESEARCH, 2021, 41 (05) : 2501 - 2509
  • [2] Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
    Lee, Jiyun
    La Choi, Yoon
    Jung, Hyun Ae
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    EUROPEAN JOURNAL OF CANCER, 2020, 132 : 150 - 158
  • [3] Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
    Imanishi, Naoko
    Hirai, Ayako
    Yoneda, Kazue
    Shimajiri, Shohei
    Kuwata, Taiji
    Tashima, Yuko
    Takeuchi, Masahiro
    Iwai, Yoshiko
    Ichiki, Yoshinobu
    Tanaka, Fumihiro
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (07) : 1563 - 1569
  • [4] Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
    Kim, Moon-Young
    Koh, Jaemoon
    Kim, Sehui
    Go, Heounjeong
    Jeon, Yoon Kyung
    Chung, Doo Hyun
    LUNG CANCER, 2015, 88 (01) : 24 - 33
  • [5] PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
    Yanhua Bai
    Dongfeng Niu
    Xiaozheng Huang
    Ling Jia
    Qiang Kang
    Fangyuan Dou
    Xinqiang Ji
    Weicheng Xue
    Yiqiang Liu
    Zhongwu Li
    Qin Feng
    Dongmei Lin
    Kennichi Kakudo
    Diagnostic Pathology, 12
  • [6] PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
    Bai, Yanhua
    Niu, Dongfeng
    Huang, Xiaozheng
    Jia, Ling
    Kang, Qiang
    Dou, Fangyuan
    Ji, Xinqiang
    Xue, Weicheng
    Liu, Yiqiang
    Li, Zhongwu
    Feng, Qin
    Lin, Dongmei
    Kakudo, Kennichi
    DIAGNOSTIC PATHOLOGY, 2017, 12
  • [7] A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis
    Naito, Maiko
    Tamiya, Akihiro
    Takeda, Maiko
    Taniguchi, Yoshihiko
    Saijo, Nobuhiko
    Naoki, Yoko
    Okishio, Kyoichi
    Yoon, Hyungeun
    Kasai, Takahiko
    Matsumura, Akihide
    Atagi, Shinji
    INTERNAL MEDICINE, 2019, 58 (07) : 921 - 927
  • [8] Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pleomorphic Lobular Breast Carcinoma
    Goker, Menekse
    Deblaere, Stephanie
    Denys, Hannelore
    Vergauwen, Glenn
    Naert, Eline
    Veldeman, Liv
    Monten, Chris
    Van den Broecke, Rudy
    Van Dorpe, Jo
    Braems, Geert
    Van de Vijver, Koen
    CANCERS, 2023, 15 (11)
  • [9] PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component
    Tanigawa, Masahiko
    Naito, Yoshiki
    Akiba, Jun
    Kawahara, Akihiko
    Okabe, Yoshinobu
    Ishida, Yusuke
    Ishikawa, Hiroto
    Hisaka, Toru
    Fujita, Fumihiko
    Yasunaga, Masafumi
    Shigaki, Takahiro
    Sudo, Tomoya
    Mihara, Yutaro
    Nakayama, Masamichi
    Kondo, Reiichiro
    Kusano, Hironori
    Shimamatsu, Kazuhide
    Okuda, Koji
    Akagi, Yoshito
    Yano, Hirohisa
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (12) : 2069 - 2074
  • [10] Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer
    Wang, Yu
    Lin, Jiacheng
    Cui, Jiujie
    Han, Ting
    Jiao, Feng
    Meng, Zhuo
    Wang, Liwei
    ONCOTARGET, 2017, 8 (06) : 9354 - 9365